These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 24007925)

  • 1. Outcomes evaluation of a weekly nurse practitioner-managed symptom management clinic for patients with head and neck cancer treated with chemoradiotherapy.
    Mason H; DeRubeis MB; Foster JC; Taylor JM; Worden FP
    Oncol Nurs Forum; 2013 Nov; 40(6):581-6. PubMed ID: 24007925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck.
    Enokida T; Ogawa T; Homma A; Okami K; Minami S; Nakanome A; Shimizu Y; Maki D; Ueda Y; Fujisawa T; Motegi A; Ohkoshi A; Taguchi J; Ebisumoto K; Nomura S; Okano S; Tahara M
    Cancer Med; 2020 Mar; 9(5):1671-1682. PubMed ID: 31943834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility and toxicity of concurrent chemoradiation for elderly patients with head and neck cancer.
    Daly ME; Lau DH; Farwell DG; Luu Q; Donald PJ; Chen AM
    Am J Otolaryngol; 2013; 34(6):631-5. PubMed ID: 23954137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensity-modulated radiation therapy with concurrent carboplatin and paclitaxel for locally advanced head and neck cancer: toxicities and efficacy.
    Vlacich G; Diaz R; Thorpe SW; Murphy BA; Kirby W; Sinard RJ; Shakhtour B; Shyr Y; Murphy P; Netterville JL; Yarbrough WG; Cmelak AJ
    Oncologist; 2012; 17(5):673-81. PubMed ID: 22550060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck.
    Suntharalingam M; Kwok Y; Goloubeva O; Parekh A; Taylor R; Wolf J; Zimrin A; Strome S; Ord R; Cullen KJ
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1845-50. PubMed ID: 21601372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Patient- and Practitioner-Reported Toxic Effects Associated With Chemoradiotherapy for Head and Neck Cancer.
    Falchook AD; Green R; Knowles ME; Amdur RJ; Mendenhall W; Hayes DN; Grilley-Olson JE; Weiss J; Reeve BB; Mitchell SA; Basch EM; Chera BS
    JAMA Otolaryngol Head Neck Surg; 2016 Jun; 142(6):517-23. PubMed ID: 27149571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction paclitaxel, carboplatin, and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Meluch AA; McClurkan S; Gray JR; Stroup SL; Burris HA; Yardley DA; Bradof JE; Yost K; Ellis JK; Greco FA
    Cancer J; 2002; 8(4):311-21. PubMed ID: 12184409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent chemoradiotherapy with weekly paclitaxel and carboplatin for locally advanced head and neck cancer: Long-term follow-up of a Brown University Oncology Group Phase II Study (HN-53).
    Chougule PB; Akhtar MS; Rathore R; Koness J; McRae R; Nigri P; Radie-Keane K; Kennedy T; Wanebo HJ; Ready N
    Head Neck; 2008 Mar; 30(3):289-96. PubMed ID: 17657799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoradiotherapy for advanced inoperable head and neck cancer: A phase II study.
    Chougule PB; Akhtar MS; Akerley W; Ready N; Safran H; McRae R; Nigri P; Bellino J; Koness J; Radie-Keane K; Wanebo H
    Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):58-63. PubMed ID: 10210541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma.
    Chung CH; Rudek MA; Kang H; Marur S; John P; Tsottles N; Bonerigo S; Veasey A; Kiess A; Quon H; Cmelak A; Murphy BA; Gilbert J
    Oral Oncol; 2016 Feb; 53():54-9. PubMed ID: 26705063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
    Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
    Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study.
    Chen AM; Felix C; Wang PC; Hsu S; Basehart V; Garst J; Beron P; Wong D; Rosove MH; Rao S; Melanson H; Kim E; Palmer D; Qi L; Kelly K; Steinberg ML; Kupelian PA; Daly ME
    Lancet Oncol; 2017 Jun; 18(6):803-811. PubMed ID: 28434660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck.
    Weiss J; Gilbert J; Deal AM; Weissler M; Hilliard C; Chera B; Murphy B; Hackman T; Liao JJ; Grilley Olson J; Hayes DN
    Oral Oncol; 2018 Sep; 84():46-51. PubMed ID: 30115475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low skeletal muscle mass is predictive of dose-limiting toxicities in head and neck cancer patients undergoing low-dose weekly cisplatin chemoradiotherapy.
    Becker JN; Hermann R; Wichmann J; Sonnhoff M; Christiansen H; Bruns F
    PLoS One; 2023; 18(2):e0282015. PubMed ID: 36802403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer.
    Vokes EE; Stenson K; Rosen FR; Kies MS; Rademaker AW; Witt ME; Brockstein BE; List MA; Fung BB; Portugal L; Mittal BB; Pelzer H; Weichselbaum RR; Haraf DJ
    J Clin Oncol; 2003 Jan; 21(2):320-6. PubMed ID: 12525525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Definitive radiochemotherapy of advanced head and neck cancer with carboplatin and paclitaxel : a phase II study.
    Semrau R; Temming S; Preuss SF; Klubmann JP; Guntinas-Lichius O; Müller RP
    Strahlenther Onkol; 2011 Oct; 187(10):645-50. PubMed ID: 21947123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis.
    Birnbaum A; Dipetrillo T; Rathore R; Anderson E; Wanebo H; Puthwala Y; Joyce D; Safran H; Henderson D; Kennedy T; Ready N; Sio TT
    Am J Clin Oncol; 2010 Apr; 33(2):144-7. PubMed ID: 19786848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck.
    Wirth LJ; Allen AM; Posner MR; Haddad RI; Li Y; Clark JR; Busse PM; Chan AW; Goguen LA; Norris CM; Annino DJ; Tishler RB
    Ann Oncol; 2010 Feb; 21(2):342-347. PubMed ID: 19892746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent paclitaxel, carboplatin, and radiotherapy in advanced head and neck cancers: a phase II study--preliminary results.
    Chougule P; Wanebo H; Akerley W; McRae R; Nigri P; Leone L; Safran H; Ready N; Koness RJ; Radie-Keane K; Cole B
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-57-S19-61. PubMed ID: 9427268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.